Enanta Pharmaceuticals Inc.'s EDP-938 hit both the primary and secondary endpoints in a Phase IIa study in respiratory syncytial virus (RSV), but a greater test likely awaits when the Boston-area firm seeks to repeat that success in a real-world setting.
Unlike many pipeline candidates for RSV, which seek to prevent infections with fusion protein inhibitor therapy, Enanta’s candidate is a...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)